Hydroxocobalamin G.L. Pharma (Hydroxocobalamin Acetate)

Hydroxocobalamin is converted inside cells to methylcobalamin and adenosylcobalamin, the active co‑enzyme forms of vitamin B12. These cofactors support methionine synthase and methylmalonyl‑CoA mutase, enzymes essential for homocysteine remethylation, fatty‑acid metabolism, DNA synthesis, and maturation of red blood cells, thereby reversing B12‑related metabolic disturbances.

The dosage of Hydroxocobalamin G.L. Pharma is determined by the prescribing clinician based on the patient’s clinical condition, severity of deficiency, and response to therapy. The prescriber will decide the appropriate amount, frequency, and duration of intramuscular administration.

Safety data for Hydroxocobalamin in pregnancy and lactation are limited. It should only be used when clearly needed, and the prescriber must weigh the potential benefits against any unknown risks to the mother and infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and import documentation.

Hydroxocobalamin has a longer plasma half‑life than cyanocobalamin and can be stored in body tissues, providing more sustained B12 levels. It also serves as an antidote for cyanide poisoning, a property not shared by most other B12 formulations, making it a preferred choice for certain clinical scenarios.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Hydroxocobalamin G.L. Pharma is administered by intramuscular injection, typically into the deltoid or gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique to minimize the risk of infection or local irritation.

Serious risks include anaphylactic reactions, severe hypotension, and rare severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be monitored for signs of allergic response, and any severe reaction requires immediate medical attention.

Individuals with known hypersensitivity to hydroxocobalamin or any component of the formulation should avoid its use. Additionally, patients receiving concurrent cyanide antidote therapy or those with severe renal impairment should be evaluated carefully by a healthcare professional before administration.